<DOC>
	<DOCNO>NCT02812524</DOCNO>
	<brief_summary>This study patient squamous cell carcinoma head neck ( SCCHN ) . This study test feasibility administration intratumoral injection ipilimumab prior surgical resection , immune system response treatment .</brief_summary>
	<brief_title>Ipilimumab Head Neck Cancer Patients</brief_title>
	<detailed_description>This study test intratumor microdosing ipilimumab ( antagonistic antibody direct Cytotoxic T-Lmphocyte-Associated Protein 4 [ CTLA-4 ] ) 7-10 day prior plan surgical resection tumor involve lymph node patient SCCHN . Tissue , peripheral blood , saliva stool sample obtain immunologic end point . The primary objective ass safety , determine number surgery delay .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients SCCHN plan surgical resection opinion surgeon able safely undergo tissue biopsy plus intratumoral ( IT ) injection advance , special consideration give risk occlusion compression airway major vessel neck , secondary tumor swelling , erosion major vessel case necrosis . Age 18 year ability give inform consent , comply protocol sign studyspecific consent document . Patients history psychiatric illness must judge investigator able understand investigational nature risk associate therapy . Any Eastern Cooperative Oncology Group ( ECOG ) performance status deem suitable investigator requirement study , potentially include incisional office biopsy lesion , image guide multiple 18g core needle biopsy ( 5 minimum ) interventional radiology , follow immediately direct injection lesion drug . Patients must blood test result within protocolspecified parameter Men must agree attempt become new father total 165 day posttreatment completion Women must agree become pregnant total 105 day post treatment completion Any clinical factor bleed , active infection , colitis history psychiatric factor judgment investigator would preclude safe participation compliance study procedure . Need chronic maintenance oral steroid â‰¥ 20mg prednisone daily equivalent ; inhale steroid acceptable . History current active autoimmune disease , [ e.g . include limited inflammatory bowel disease ( IBD ) , rheumatoid arthritis , autoimmune thyroiditis , autoimmune hepatitis , systemic sclerosis ( scleroderma variant ) , systemic lupus erythematosus , autoimmune vasculitis , autoimmune neuropathy ( GuillainBarre syndrome ) , judgment investigator pose active significant risk . Vitiligo adequately control endocrine deficiency hypothyroidism exclusionary . ] Infectious disease include human immunodeficiency virus ( HIV ) , Hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . Patients history acute diverticulitis , intraabdominal abscess , GI obstruction abdominal carcinomatosis know risk factor bowel perforation , judgment investigator still pose active risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Yervoy</keyword>
	<keyword>Head neck cancer</keyword>
	<keyword>Pre-operative</keyword>
</DOC>